Data / Drug companies / Norepinephrine bitartrate
Norepinephrine bitartrate: 25 companies and 37 products in the FDA NDC directory
Norepinephrine bitartrate is listed in the FDA National Drug Code Directory by 25 companies, with 37 products in commercial distribution. 22 of the products (59.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution, concentrate; injection, solution; injection, and the newest product started marketing on October 30, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 25
- Products
- 37
- Generic (ANDA) products
- 22 (59.5%)
- Application numbers
- 17
- Routes
- Intravenous
- Brand names
- Norepinephrine, Levophed
- openFDA record search
- api.fda.gov
Companies that list norepinephrine bitartrate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Baxter Healthcare Corporation | 6 | injection, solution | New drug applications (NDA) | November 21, 2023 |
| WG Critical Care, LLC | 4 | injection, solution | New drug applications (NDA) | September 15, 2022 |
| Long Grove Pharmaceuticals, LLC | 3 | solution | New drug applications (NDA) | February 2, 2024 |
| Hospira, Inc. | 2 | injection, solution, concentrate | New drug applications (NDA) | March 11, 2024 |
| NorthStar RxLLC | 2 | injection; injection, solution, concentrate | Generic drugs (ANDA) | October 30, 2026 |
| Anthea Pharma Private Limited | 1 | injection, solution, concentrate | Generic drugs (ANDA) | November 25, 2025 |
| Avenacy, LLC | 1 | injection, solution | Generic drugs (ANDA) | February 1, 2026 |
| Baxter Healthcare Corporation | 1 | injection | Generic drugs (ANDA) | May 6, 2021 |
| Be Pharmaceuticals Inc. | 1 | injection | Generic drugs (ANDA) | December 30, 2023 |
| Biocon Pharma Inc. | 1 | injection, solution, concentrate | Generic drugs (ANDA) | July 1, 2025 |
| Breckenridge Pharmaceutical, Inc. | 1 | injection, solution, concentrate | Generic drugs (ANDA) | July 1, 2021 |
| Camber Pharmaceuticals, Inc. | 1 | injection, solution, concentrate | Generic drugs (ANDA) | January 31, 2025 |
| Caplin Steriles Limited | 1 | injection | Generic drugs (ANDA) | September 28, 2024 |
| Civica, Inc. | 1 | injection, solution, concentrate | Generic drugs (ANDA) | March 12, 2021 |
| Fresenius Kabi USA, LLC | 1 | solution | Generic drugs (ANDA) | March 1, 2021 |
| Fresenius Kabi USA, LLC | 1 | solution | Generic drugs (ANDA) | March 1, 2021 |
| Gland Pharma Limited | 1 | injection | Generic drugs (ANDA) | May 12, 2021 |
| HF Acquisition Co LLC, DBA HealthFirst | 1 | injection | Generic drugs (ANDA) | August 8, 2021 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection | Generic drugs (ANDA) | August 1, 2018 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, solution, concentrate | Generic drugs (ANDA) | December 1, 2024 |
| Mylan Institutional LLC | 1 | injection, solution, concentrate | Generic drugs (ANDA) | October 15, 2018 |
| Novadoz Pharmaceuticals LLC | 1 | injection, solution, concentrate | Generic drugs (ANDA) | December 11, 2025 |
| Rising Pharma Holdings, Inc. | 1 | injection | Generic drugs (ANDA) | November 1, 2024 |
| Sagent Pharmaceuticals | 1 | injection, solution | Generic drugs (ANDA) | July 1, 2021 |
| Sandoz Inc | 1 | injection, solution, concentrate | Generic drugs (ANDA) | April 23, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution, concentrate | 12 | 32.4% |
| Injection, solution | 12 | 32.4% |
| Injection | 8 | 21.6% |
| Solution | 5 | 13.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 59.5% |
| New drug applications (NDA) | 15 | 40.5% |
Pharmacologic classes
| Class | Products |
|---|---|
| Catecholamine | 37 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.